Gong, J., Shen, L., Dong, Z., Liu, D., Xu, J., Yang, J., Yang, Y., et al. (2020) 810 Preliminary Safety, Tolerability and Efficacy Results of KN026 in Combination with KN046 in Patients with HER2 Aberrated Solid Tumors. Journal for ImmunoTherapy of Cancer, 8, A485-A486.
https://doi.org/10.1136/jitc-2020-SITC2020.0810

has been cited by the following article:

• TITLE: Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

  AUTHORS: Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian

  KEYWORDS: Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.